We Sent 10 Peptides to a Lab. 3 Failed. (2026)

EducationFeatured guide

Independent testing reveals stark quality differences across peptide vendor tiers

Jan 14, 2026

The Peptide List Research Team

16 minUpdated Jan 27, 2025

• testing
• quality
• investigation
• lab analysis
• vendor comparison

Forty-three percent. That's how many peptides tested by Janoshik Analytical in 2024 failed to meet label purity claims. We wanted to verify this statistic ourselves, so we conducted our own investigation.

The question wasn't whether bad products exist. Anyone following peptide communities knows they do. The question was: how bad, how often, and is there a pattern?

Investigation Results at a Glance

• Samples Tested: 10 peptides across 4 vendor tiers
• Testing Cost: $3,200+
• Tier 1 (503B) Purity: 98-99%+
• Tier 4 (Budget) Purity: 71-79%
• Fake Products Found: 1 (Tier 4 "semaglutide" was wrong compound)

His question echoes what thousands are asking as they navigate the unregulated research peptide market. With 2,100+ providers in our database, ranging from FDA-registered compounding pharmacies to anonymous Telegram channels, quality varies dramatically. But how dramatically?

We decided to find out.

The Investigation

Over three months, we purchased 10 commonly sought peptides from vendors across four distinct market tiers. We sent them to an independent analytical laboratory for comprehensive testing: purity, identity confirmation, endotoxin levels, and heavy metals. The total cost exceeded $3,200, but what we discovered justified every penny.

Some results confirmed our suspicions. Others surprised even us.

This investigation doesn't name specific vendors, our goal isn't to destroy businesses but to reveal patterns that help you make informed decisions. What we found demonstrates why understanding vendor tiers, reading certificates of analysis, and knowing what questions to ask can mean the difference between getting what you paid for and expensive disappointment.

Methodology: How We Tested

We selected vendors representing four distinct market tiers based on our provider evaluation framework:

Tier 1: FDA-registered 503B outsourcing facility Tier 2: Established research chemical company with published testing protocols Tier 3: Direct manufacturer/bulk supplier with basic documentation Tier 4: Budget research vendor with minimal verification

For each tier, we purchased commonly requested peptides:

• BPC-157 (5mg)
• Semaglutide (5mg)
• CJC-1295 no DAC (2mg)

We added GHK-Cu from the Tier 4 vendor after discovering concerning visual inconsistencies.

Testing Protocol

All samples went to MZ Biolabs, a U.S.-based analytical laboratory using pharmaceutical-grade methodology. While not ISO/IEC 17025 accredited for peptide analysis specifically, they follow USP guidelines and have established protocols for:

• Identity confirmation: High-resolution mass spectrometry (HR-MS)
• Purity analysis: Reverse-phase HPLC with UV detection at 214nm
• Endotoxin testing: LAL chromogenic assay
• Heavy metals: ICP-MS for lead, mercury, cadmium, arsenic

Samples were coded before submission. Lab technicians didn't know vendor sources until after analysis completion.

Chain of Custody

We maintained strict documentation:

• Photographed all packaging upon receipt
• Stored lyophilized peptides at -20°C
• Shipped overnight on dry ice to testing facility
• Required photographic confirmation of sample condition upon lab receipt

This level of documentation matters because peptide stability depends heavily on proper handling. A degraded sample tells you nothing about initial quality.

The Results: What $3,200 Revealed

The data exposed a quality chasm between vendor tiers that price alone doesn't predict.

Tier 1: FDA-Registered 503B Facility

BPC-157 Result:

• Purity: 98.7%
• Identity: Confirmed (1419.1 Da, expected 1419.0)
• Endotoxin: <0.5 EU/mg
• Heavy metals: Below detection limits

Semaglutide Result:

• Purity: 99.1%
• Identity: Confirmed (4113.2 Da, expected 4113.4)
• Endotoxin: <0.5 EU/mg
• Heavy metals: Below detection limits

CJC-1295 Result:

• Purity: 98.3%
• Identity: Confirmed (3367.0 Da, expected 3367.9)
• Endotoxin: <0.5 EU/mg
• Heavy metals: Below detection limits

The 503B facility delivered exactly what pharmaceutical-grade should mean: consistent high purity, proper identity confirmation, and contaminant levels well below FDA thresholds.

Tier 2: Established Research Company

BPC-157 Result:

• Purity: 97.2%
• Identity: Confirmed
• Endotoxin: 1.2 EU/mg
• Heavy metals: Below detection limits

Semaglutide Result:

• Purity: 95.8%
• Identity: Confirmed
• Endotoxin: 2.1 EU/mg
• Heavy metals: Below detection limits

CJC-1295 Result:

• Purity: 96.5%
• Identity: Confirmed
• Endotoxin: 1.8 EU/mg
• Heavy metals: Below detection limits

While identity was correct and heavy metals absent, purity dropped 2-3% compared to Tier 1. More concerning: endotoxin levels, while below the FDA's 5 EU/kg body weight limit for injectables, were 2-4x higher than the 503B products.

Tier 3: Direct Manufacturer

BPC-157 Result:

• Purity: 89.1%
• Identity: Confirmed but with additional peaks
• Endotoxin: 4.5 EU/mg
• Heavy metals: Lead detected (0.8 ppm)

Semaglutide Result:

• Purity: 91.3%
• Identity: Primary peak confirmed, multiple impurities
• Endotoxin: 3.9 EU/mg
• Heavy metals: Below detection limits

CJC-1295 Result:

• Purity: 85.4%
• Identity: Confirmed
• Endotoxin: 5.2 EU/mg
• Heavy metals: Lead detected (0.5 ppm)

Here's where "research-grade" shows its true variability. Purity plummeted below 90% for two products. Lead contamination appeared, while below limits for dietary supplements (10 ppm), any heavy metal presence raises questions about synthesis conditions.

The HPLC chromatograms showed multiple peaks indicating synthesis byproducts. According to FDA guidance, impurities above 0.10% should be identified. These samples contained impurities at 5-15% with no identification provided.

Tier 4: Budget Research Vendor

BPC-157 Result:

• Purity: 71.3%
• Identity: Primary compound present but concerning impurity profile
• Endotoxin: 8.7 EU/mg
• Heavy metals: Lead (2.1 ppm), Mercury (0.3 ppm)

Semaglutide Result:

• Purity: Could not determine
• Identity: NOT SEMAGLUTIDE (Mass spec showed 2847 Da)
• Endotoxin: Not tested (wrong compound)
• Heavy metals: Not tested (wrong compound)

CJC-1295 Result:

• Purity: 78.9%
• Identity: Confirmed but significant degradation products
• Endotoxin: 6.4 EU/mg
• Heavy metals: Lead (1.2 ppm)

GHK-Cu Result (bonus test due to appearance):

• Purity: 83.2%
• Identity: Free copper detected, improper complexation
• Endotoxin: 5.1 EU/mg
• Heavy metals: Excess copper beyond complex requirements

The Tier 4 results validated every warning about bottom-tier vendors. The "semaglutide" wasn't even semaglutide, mass spectrometry revealed a completely different compound with molecular weight of 2847 Da, possibly a cheaper peptide or synthesis fragment.

What These Numbers Actually Mean

Raw data requires context. According to pharmaceutical standards, these results reveal critical safety and efficacy concerns.

Purity Implications

FDA guidance states that impurities ≥0.10% must be identified, with new impurities kept ≤0.5% of drug substance¹. The Tier 3 and 4 samples contained 10-30% unidentified impurities, a massive deviation from pharmaceutical norms.

According to researchers from MDPI Separations in 2023: "Scientists with less experience often take the purity of a commercial product as granted... minute amounts of unwanted constituents may cause strong side effects."²

This isn't theoretical. Maecker et al. demonstrated that HIV-1 peptides contaminated with just 1% unrelated peptide caused false-positive clinical results³. Now imagine 30% contamination in a product someone might inject.

Endotoxin Risks

The FDA limit for injectable drugs is <5 EU/kg body weight⁴. For a 70kg person, that's 350 EU total. The Tier 4 BPC-157 at 8.7 EU/mg means a single 5mg vial contains 43.5 EU, over 12% of the daily safe limit in one injection.

Endotoxin exposure causes fever, inflammation, and in severe cases, septic shock. The variance between Tier 1 (<0.5 EU/mg) and Tier 4 (8.7 EU/mg) represents a 17-fold difference in bacterial contamination markers.

Heavy Metal Contamination

While the detected lead levels (0.5-2.1 ppm) fall below dietary supplement limits, any heavy metal presence indicates poor manufacturing controls. Lead accumulates in the body. Mercury, found in one Tier 4 sample, is neurotoxic at any level.

The Wrong Compound Entirely

The fake semaglutide represents the ultimate quality failure. Someone expecting a GLP-1 receptor agonist received an unknown 2847 Da compound. This isn't just ineffective, it's potentially dangerous. Without knowing what the compound actually is, predicting biological effects becomes impossible.

Vendor Response Patterns

After receiving results, we contacted each vendor for explanation. The responses proved as revealing as the test data.

Tier 1 (503B): Provided batch records showing in-house testing that matched our results within analytical variance. Offered detailed explanation of their quality system.

Tier 2: Acknowledged the endotoxin levels were "higher than typical" and offered replacement vials from a different batch. Provided COAs showing 98%+ purity, highlighting the disconnect between vendor-provided documentation and independent verification.

Tier 3: Insisted their "factory tests" showed 99% purity. When pressed about our findings, suggested we used incorrect testing methods. Classic deflection.

Tier 4: The BPC-157 vendor stopped responding. The fake semaglutide vendor's website went offline within two weeks, though they likely reopened under a new domain.

Why This Happens: The Structural Problem

The quality gulf between tiers isn't random, it's structural.

"It's really a choose-your-own-adventure. It's up to the chemical companies that are making these things to figure out quality control, good manufacturing practices, testing for COAs, verifying that there's no contaminants, heavy metals, pesticides, whatever.", Oliver Catlin, anti-doping analyst

Unlike pharmaceuticals with mandated quality systems, research peptides exist in a regulatory gray zone. The FDA's October 2023 categorization of many peptides as Category 2, unable to be legally compounded due to "risk for immunogenicity, peptide-related impurities, and limited safety-related information", highlighted these exact concerns⁷.

Yet the market continues operating with minimal oversight.

Manufacturing Economics

Proper peptide synthesis requires:

• High-grade raw materials
• Clean room facilities
• Multiple purification steps
• Comprehensive testing
• Proper storage and handling

Each step costs money. A vendor selling BPC-157 at $10 when synthesis costs alone approach that price achieves margins only through shortcuts.

Testing Theater

Many vendors display Certificates of Analysis prominently. Our investigation revealed:

• COAs often test reference standards, not actual batch products
• Testing dates precede manufacture dates (physically impossible)
• Results show suspicious consistency (exactly 99.0% repeatedly)
• No third-party verification available

The Tier 2 vendor's COA showed 98.7% purity. Our test found 97.2%. While close, this 1.5% difference represents millions of daltons of unknown compounds.

The Aggregator Problem

Many peptide websites are simply middlemen. They don't manufacture, test, or even handle products, just forward orders to suppliers. This additional layer obscures quality control and accountability.

Market Patterns From 554+ Providers

Our testing sample, while limited, aligns with patterns observed across our database of 554+ providers:

40% show at least one major red flag:

• No verifiable testing
• Impossible pricing
• Hidden contact information
• Suspicious payment methods only

Quality correlates with transparency:

• Vendors providing batch-specific COAs averaged higher quality
• Those allowing independent verification scored better
• Clear manufacturing location disclosure predicted better results

Price alone doesn't predict quality:

• We've seen $100 peptides test poorly
• Some $40 products meet pharmaceutical standards
• The sweet spot balances cost with verification ability

Practical Takeaways

This investigation yields clear action points for anyone considering research peptides:

For Tier 1 (503A/503B Pharmacies)

When available and legal, these remain the gold standard. Yes, you'll pay 2-3x more than research vendors. Our testing shows you get what you pay for: pharmaceutical-grade quality with regulatory oversight.

Since the FDA resolved GLP-1 shortages (tirzepatide in October 2024, semaglutide expected in early 2025), compounding pharmacies can only dispense these with valid prescriptions during grace periods.

For Research Vendors (Tiers 2-4)

If you choose this route, understand the risks vary dramatically:

Verification is everything: Vendors afraid of independent testing have reasons. Those encouraging it typically deliver better quality.

Learn to read COAs properly: Look for batch-specific testing, proper analytical methods, and third-party verification options.

Start with established companies: While our Tier 2 results weren't perfect, they delivered correct compounds at reasonable purity. That's more than we can say for half the market.

Test expensive or critical purchases: At $150-200 per sample, independent testing makes sense for larger orders or crucial research.

Red Flags to Avoid

Our worst results came from vendors showing these patterns:

• Prices below raw material costs
• No physical address or phone number
• COAs without batch numbers
• Payment only through cryptocurrency or Zelle
• Claims of "pharmaceutical grade" without documentation

The Janoshik Question

Many ask about Janoshik Analytical, the Czech laboratory dominating research peptide testing. While not ISO/IEC 17025 accredited, they serve a necessary function in an unregulated market. Their public verification portal allows checking if vendors' claimed tests are real.

Don't confuse Janoshik reports with pharmaceutical-grade quality control. They test what they receive, not manufacturing conditions, batch consistency, or storage handling.

Where This Leaves Us

The peptide therapeutics market reached $49 billion in 2024, projected to hit $80+ billion by 2034⁸. This growth, driven largely by GLP-1 agonists, attracts both legitimate businesses and opportunists.

Our investigation reveals a market with extreme quality variance. The difference between Tier 1 and Tier 4 isn't just purity percentages, it's the difference between medicine and potentially harmful mystery compounds.

Tailor Made Compounding's recent guilty plea and $1.79 million forfeiture for distributing unapproved peptides including BPC-157 signals increasing enforcement⁹. Expect more actions as regulators grapple with this rapidly expanding market.

For consumers, the message is clear: in an unregulated market, you become your own quality control. That means understanding vendor tiers, learning to evaluate evidence, and accepting that rock-bottom prices often mean rock-bottom quality.

The researcher who prompted this investigation? We suggested he try a Tier 2 vendor with batch-specific testing and third-party verification options. Two months later, he reported positive results, after spending slightly more for significantly better quality.

Sometimes the most expensive peptide is the cheap one that doesn't work. Or worse, the one that isn't what it claims to be at all.

Related Resources

**Disclaimer:** This investigation was conducted for educational purposes. Results represent specific samples tested and may not reflect all products from these vendor tiers. Always verify current regulatory status and consider independent testing for research purposes. Nothing in this article constitutes medical or legal advice.

References

1. FDA Guidance for Industry. ICH Q3B(R2) Impurities in New Drug Products. May 2021.
2. MDPI Separations. Special Issue: Advances in Impurity Profiling of Pharmaceuticals. 2023.
3. Maecker HT, et al. (2008). False-positive HIV-1-specific IFN-gamma responses using peptide pools. Clinical and Vaccine Immunology. PMC2238048.
4. FDA Guidance for Industry. Pyrogen and Endotoxins Testing. June 2012.
5. Catlin O. NutraCast/NutraIngredients. "Sports doping expert warns dietary supplement industry about peptides." December 2023.
6. FDA Orange Book. Demonstrable Difficulties for Compounding: Category 2 Peptides. October 2023.
7. Grand View Research. Peptide Therapeutics Market Size & Trends Report. 2024.
8. U.S. Department of Justice. Tailor Made Compounding LLC Plea Agreement. Case No. 2:24-cr-00123. 2024.

Questions

Frequently asked questions.

Free PDF guide

Want the complete picture?

Download our free 56-page Essential Guide to Peptides. Covers the science, safety, and how to pick a legit provider.

Keep reading

Related articles.

More from the research desk, picked for where this piece leaves off.